Ohcanbohtosat - Pascal Wolter

  • Čájehuvvo 1 - 18 / 18
Aiddostahte ozu
  1. 1
    The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation

    The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation Dahkki Pascal Wolter, Cristiana Stefan, Brigitte Decallonne, Herlinde Dumez, M Bex, Peter Carmeliet, Patrick Schöffski

    Almmustuhtton 2008
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  2. 2
    Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review

    Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review Dahkki Patrick Schöffski, Herlinde Dumez, Paul M. Clément, Ann Hoeben, Hans Prenen, Pascal Wolter, Steven Joniau, Tania Roskams, Hendrik Van Poppel

    Almmustuhtton 2006
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  3. 3
    An important role for Myb-MuvB and its target gene KIF23 in a mouse model of lung adenocarcinoma

    An important role for Myb-MuvB and its target gene KIF23 in a mouse model of lung adenocarcinoma Dahkki Fabian Iltzsche, Katalenić Simon, Sabine Stopp, Grit Pattschull, Stephan Francke, Pascal Wolter, Stefanie Hauser, Daniel J. Murphy, Paloma García, Andreas Rosenwald, Stefan Gaubatz

    Almmustuhtton 2016
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  4. 4
    Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib

    Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib Dahkki Benoit Beuselinck, Stéphane Oudard, Olivier Rixe, Pascal Wolter, Aurore Blesius, J. Ayllón, Réza Elaidi, Patrick Schöffski, Eduardo Barrascout, Alexandre Morel, Bernard Escudier, H. Lang, Jessica Zucman‐Rossi, Jacques Médioni

    Almmustuhtton 2010
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  5. 5
    Independent replication of a melanoma subtype gene signature and evaluation of its prognostic value and biological correlates in a population cohort

    Independent replication of a melanoma subtype gene signature and evaluation of its prognostic value and biological correlates in a population cohort Dahkki Jérémie Nsengimana, Jon Laye, Anastasia Filia, Christy Walker, Rosalyn Jewell, Joost J. van den Oord, Pascal Wolter, Poulam M. Patel, Antje Sucker, Dirk Schadendorf, Göran Jönsson, D. Timothy Bishop, Julia Newton‐Bishop

    Almmustuhtton 2015
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  6. 6
    Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases

    Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases Dahkki Benoit Beuselinck, Pascal Wolter, Alexandra Karadimou, Réza Elaidi, Herlinde Dumez, Anne Rogiers, Thomas Van Cann, Ludo Willems, J.J. Body, J. Berkers, Hendrik Van Poppel, Evelyne Lerut, Philip R. Debruyne, Robert Paridaens, Patrick Schöffski

    Almmustuhtton 2012
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  7. 7
    MGMT promoter methylation is associated with temozolomide response and prolonged progression‐free survival in disseminated cutaneous melanoma

    MGMT promoter methylation is associated with temozolomide response and prolonged progression‐free survival in disseminated cutaneous melanoma Dahkki Rainer Tuominen, Rosalyn Jewell, Joost J. van den Oord, Pascal Wolter, Ulrika Stierner, Christer Lindholm, Carolina Johansson, Diana Lindén, Hemming Johansson, Marianne Frostvik Stolt, Christy Walker, Helen Snowden, Julia Newton‐Bishop, Johan Hansson, Suzanne Egyházi Brage

    Almmustuhtton 2014
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  8. 8
    Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial

    Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinic... Dahkki Matteo S. Carlino, Georgina V. Long, Dirk Schadendorf, Caroline Robert, Antoni Ribas, Erika Richtig, Marta Nyakas, Christian Caglevic, Ahmed Tarhini, Christian U. Blank, Christoph Höeller, Gil Bar‐Sela, Catherine Barrow, Pascal Wolter, Haiyu Zhou, Kenneth Emancipator, Erin Jensen, Scot Ebbinghaus, Nageatte Ibrahim, Adil Daud

    Almmustuhtton 2018
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  9. 9
    Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib

    Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib Dahkki Benoit Beuselinck, Alexandra Karadimou, Diether Lambrechts, Bart Claes, Pascal Wolter, Gabrielle Couchy, J. Berkers, Robert Paridaens, Patrick Schöffski, Arnaud Méjean, Virginie Verkarre, Evelyne Lerut, A. De La Taille, J.M. Tourani, Pierre Bigot, Claude Linassier, Sylvie Négrier, Jérôme Berger, J.J. Patard, Jessica Zucman‐Rossi, Stéphane Oudard

    Almmustuhtton 2013
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  10. 10
    Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study

    Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study Dahkki Dirk Schadendorf, Mayur M. Amonkar, Mohammed Milhem, Karen R. Grotzinger, Lev Demidov, Piotr Rutkowski, Claus Garbe, Reinhard Dummer, Jessica C. Hassel, Pascal Wolter, Peter Mohr, Uwe Trefzer, Claudia Lefeuvre‐Plesse, Annemie Rutten, Neil Steven, Gustav Ullenhag, Laurie Sherman, Frank Wu, Kirtan Patel, Michelle Casey, Caroline Robert

    Almmustuhtton 2014
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  11. 11
    VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib – a multicentric retrospective analysis

    VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib – a multicentric retrospective analysis Dahkki Benoit Beuselinck, Alexandra Karadimou, Diether Lambrechts, Bart Claes, Pascal Wolter, Gabrielle Couchy, Joost Berkers, Hendrik Van Poppel, Robert Paridaens, Patrick Schöffski, Arnaud Méjean, Virginie Verkarre, Evelyne Lerut, Florence Joly, Thierry Lebrét, Gwénaëlle Gravis, G. Deplanque, A. Descazeaud, Nathalie Leclercq, Vincent Molinié, Jean‐Jacques Patard, Corine Teghom, Réza Elaidi, Jessica Zucman‐Rossi, Stéphane Oudard

    Almmustuhtton 2013
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  12. 12
    Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

    Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib Dahkki Caroline Robert, Bogusława Karaszewska, Jacob Schachter, Piotr Rutkowski, Andrzej Maćkiewicz, D. Stroiakovski, M. Lichinitser, Reinhard Dummer, Florent Grange, Laurent Mortier, Vanna Chiarion‐Sileni, Kamil Drucis, Ivana Krajsová, Axel Hauschild, Paul Lorigan, Pascal Wolter, Georgina V. Long, Keith T. Flaherty, Paul Nathan, Antoni Ribas, Anne-Marie Martin, Peng Sun, Wendy Crist, Jeff Legos, Stephen D. Rubin, Shonda M Little, Dirk Schadendorf

    Almmustuhtton 2014
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  13. 13
    PATIENT‐REPORTED OUTCOMES AND QUALITY OF LIFE IN PATIENTS WITH CUTANEOUS T CELL LYMPHOMA: RESULTS FROM THE PHASE 3 ALCANZA STUDY

    PATIENT‐REPORTED OUTCOMES AND QUALITY OF LIFE IN PATIENTS WITH CUTANEOUS T CELL LYMPHOMA: RESULTS FROM THE PHASE 3 ALCANZA STUDY Dahkki H. Miles Prince, Reinhard Dummer, Sean Whittaker, Steve Horwitz, Madeleine Duvic, Julia Scarisbrick, Pietro Quaglino, Pier Luigi Zinzani, Pascal Wolter, José Antônio Sanches, Pablo L. Ortiz‐Romero, Oleg E. Akilov, Larisa J. Geskin, Auris Huen, Y. Wang, Maria Corinna Palanca-Wessels, Akshara Richhariya, Joseph Feliciano, Yanyan Zhu, Huamao Mark Lin, Y. Liu, Melissa H. Little, Erin Zagadailov, Mehul Dalal, Y.H. Kim

    Almmustuhtton 2017
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  14. 14
    RESPONSE BY STAGE IN CD30‐POSITIVE (CD30+) CUTANEOUS T CELL LYMPHOMA (CTCL) PATIENTS RECEIVING BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN THE PHASE 3 ALCANZA STUDY

    RESPONSE BY STAGE IN CD30‐POSITIVE (CD30+) CUTANEOUS T CELL LYMPHOMA (CTCL) PATIENTS RECEIVING BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN THE PHASE 3 ALCANZA STUDY Dahkki Sarah McCue Horwitz, Sean Whittaker, Madeleine Duvic, Reinhard Dummer, Y.H. Kim, Julia Scarisbrick, Pietro Quaglino, Pier Luigi Zinzani, Pascal Wolter, Herbert Eradat, José Antônio Sanches, Pablo L. Ortiz‐Romero, Oleg E. Akilov, Judith Trotman, Kerry Taylor, Stéphane Dalle, Michael Weichenthal, Jan Walewski, David C. Fisher, Y. Wang, Maria Corinna Palanca-Wessels, Huimin Lin, Y. Liu, Melissa H. Little, H. Miles Prince

    Almmustuhtton 2017
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  15. 15
    Toward Minimal Residual Disease-Directed Therapy in Melanoma

    Toward Minimal Residual Disease-Directed Therapy in Melanoma Dahkki Florian Rambow, Aljosja Rogiers, Oskar Marín-Béjar, Sara Aibar, Julia Femel, Michael Dewaele, Panagiotis Karras, Daniel V. Brown, Young Hwan Chang, Maria Dębiec‐Rychter, Carmen Adriaens, Enrico Radaelli, Pascal Wolter, Oliver Bechter, Reinhard Dummer, Mitchell P. Levesque, Adriano Piris, Dennie T. Frederick, Genevieve M. Boland, Keith T. Flaherty, Joost van den Oord, Thierry Voet, Stein Aerts, Amanda W. Lund, Jean‐Christophe Marine

    Almmustuhtton 2018
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  16. 16
    Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)

    Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT) Dahkki Richard D. Carvajal, Sophie Piperno‐Neumann, Ellen Kapiteijn, Paul B. Chapman, Stephen Jay Frank, Anthony M. Joshua, Josep M. Piulats, Pascal Wolter, Véronique Cocquyt, Bartosz Chmielowski, T.R. Jeffry Evans, Lauris Gastaud, Gerald P. Linette, Carola Berking, Jacob Schachter, Manuel Rodrigues, Alexander N. Shoushtari, Delyth Clemett, Dana Ghiorghiu, G Mariani, Shirley Spratt, Susan Lovick, Peter Barker, Elaine Kilgour, Zhongwu Lai, Gary K. Schwartz, Paul Nathan

    Almmustuhtton 2018
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  17. 17
    Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study

    Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study Dahkki Reinhard Dummer, H. Miles Prince, Sean Whittaker, Sarah McCue Horwitz, Youn H. Kim, Julia Scarisbrick, Pietro Quaglino, Pier Luigi Zinzani, Pascal Wolter, Herbert Eradat, Lauren Pinter‐Brown, José Antônio Sanches, Pablo L. Ortiz‐Romero, Oleg E. Akilov, Larisa J. Geskin, Auris Huen, Jan Walewski, Yinghui Wang, Julie Lisano, Akshara Richhariya, Joseph Feliciano, Yanyan Zhu, Veronica Bunn, Meredith Little, Erin Zagadailov, Mehul Dalal, Madeleine Duvic

    Almmustuhtton 2020
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  18. 18
    Response to brentuximab vedotin versus physician’s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis

    Response to brentuximab vedotin versus physician’s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis Dahkki Youn H. Kim, H. Miles Prince, Sean Whittaker, Sarah McCue Horwitz, Madeleine Duvic, Oliver Bechter, José Antônio Sanches, Rudolf Stadler, Julia Scarisbrick, Pietro Quaglino, Pier Luigi Zinzani, Pascal Wolter, Herbert Eradat, Lauren Pinter‐Brown, Pablo L. Ortiz‐Romero, Oleg E. Akilov, Judith Trotman, Kerry Taylor, Michael Weichenthal, Jan Walewski, David C. Fisher, Marise McNeeley, Alejandro A. Gru, Lisa Brown, Maria Corinna Palanca-Wessels, Julie Lisano, Matthew Onsum, Veronica Bunn, Meredith Little, William L. Trepicchio, Reinhard Dummer

    Almmustuhtton 2021
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:

Ohcanreaiddut: